Overview
Rachelle Dillon practices practicing medicine in Winnipeg, Canada.
Her clinical expertise encompasses Bladder Cancer, Lung Metastases, and Non-Muscle Invasive Bladder Cancer.
She is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Rachelle L. Dillon
Is Rachelle L. Dillon a top-rated expert for Bladder Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Rachelle L. Dillon is classified as an Experienced expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Rachelle L. Dillon participate in research or clinical trials?
Yes. Rachelle L. Dillon has published 8 articles and abstracts on conditions like Bladder Cancer. You can view a list of Rachelle L. Dillon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Bladder CancerMs. Dillon isExperienced. Learn about Bladder Cancer.
- Lung MetastasesMs. Dillon isExperienced. Learn about Lung Metastases.
- Non-Muscle Invasive Bladder CancerMs. Dillon isExperienced. Learn about Non-Muscle Invasive Bladder Cancer.